3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Carcinoma, Renal Cell
4
Neoplasm Metastasis
3
Melanoma
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Metastatic Castration-resistant Prostate Cancer
1
Kidney Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Docetaxel
35
pembrolizumab
32
Nivolumab
27
enzalutamide
20
Prednisone
20
Sunitinib
16
Cyclophosphamide
16
aldesleukin
14
Zoledronic Acid
13
Interleukin-2
13
Gemcitabine
13
Bevacizumab
13
Specimen Handling
12
Ipilimumab
12
Radiosurgery
11
Everolimus
11
Androgen Antagonists
11
Abiraterone Acetate
11
fludarabine
10
Sorafenib
10
Radiotherapy
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
pazopanib
9
abiraterone
9
Doxorubicin
8
Carboplatin
8
Biopsy
8
avelumab
7
temsirolimus
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
bempegaldesleukin
×
Genitourinary
×
Clear all
NCT03785925
2023-03-28
PIVOT-10
Nektar Therapeutics
Phase 2
Completed
192 enrolled
16 charts
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts